X4 Pharmaceuticals Inc. (NASDAQ:XFOR) finished Thursday with a subtraction of -$0.59 to close at $1.05, a downside of -35.98 percent. An average of 4,870,540 shares of common stock have been traded in the last five days. There was a fall of -$0.7300 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 2,658,525 shares traded, while the 50-day average volume stands at 3,088,482.
XFOR stock has decreased by -44.74% in the last month. The company shares reached their 1-month lowest point of $1.0000 on 08/10/23. With the stock rallying to its 52-week high on 06/13/23, shares of the company touched a low of $0.65 and a high of $2.58 in 52 weeks. It has reached a new high 23 times so far this year and achieved 5.74% or $0.0570 in price. In spite of this, the price is down -59.22% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
XFOR stock investors should be aware that X4 Pharmaceuticals Inc. (XFOR) stock had its last reported insider trading activity 42 days ago on Jun 30. In this transaction, the insider spent $4,991. Chief Operating Officer, DiBiase Mary, disposed of 464 shares at a price of $1.89 on Jun 30. The insider now owns more than $877 worth of shares. Prior to that, President and CEO Ragan Paula went on to Sale 6,724 shares at $1.92 each on Jun 23. An amount of $12,910 was transacted.
Valuation Metrics
X4 Pharmaceuticals Inc. (XFOR) stock’s beta is 0.70. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.00.
Financial Health
The quick ratio of X4 Pharmaceuticals Inc. for the three months ended March 30 was 5.00, and the current ratio was 5.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.62 and a total debt to equity ratio of 0.63 for the quarter ending March 30. Its gross profit as reported stood at $87.57 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, X4 Pharmaceuticals Inc.’s return on assets was -81.10%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$24.02 million in the quarter, while revenues of -$29.1 million were shrunk -0.83%. The analyst consensus anticipated X4 Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.16, a 27.30% surprise. For the quarter, EBITDA amounted to -$29.18 million. Shareholders own equity worth $122.21 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at X4 Pharmaceuticals Inc. (XFOR) price momentum. RSI 9-day as of the close on 10 August was 15.24%, suggesting the stock is oversold, with historical volatility in this time frame at 224.31%.
As of today, XFOR’s price is $1.5640 -41.01% or -$0.7300 from its 5-day moving average. XFOR is currently trading -44.44% lower than its 20-day SMA and +25.00% higher than its 100-day SMA. However, the stock’s current price level is -45.60% below the SMA50 and -47.50% below the SMA200.
The stochastic %K and %D were 13.07% and 17.79%, respectively, and the average true range (ATR) was 0.1728. With the 14-day stochastic at 5.68% and the average true range at 0.1599, the RSI (14) stands at 22.17%. The stock has reached -0.1922 on the 9-day MACD Oscillator while the 14-day reading was at -0.2336.
Analyst Ratings
Cantor Fitzgerald launched coverage on X4 Pharmaceuticals Inc. (NASDAQ: XFOR) in its analyst report released on December 22, 2022. The firm assigned the stock an Overweight rating. The consensus rating for X4 Pharmaceuticals Inc. (XFOR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell XFOR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is XFOR’s price target for the next 12 months?
Analysts predict a range of price targets between $2.60 and $5.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for X4 Pharmaceuticals Inc. (XFOR) stock is $3.76.
